Background. Sepsis remains one of the leading causes of infant death worldwide. It is characterized by uncontrolled inflammatory responses due to proven bacterial infection. Despite improvement in supportive care and the availability of effective antibiotics, no specific therapy targeting the dysregulated inflammatory response is available for neonatal sepsis. Milk fat globule epidermal growth factor-factor 8 (MFG-E8) is a secretory glycoprotein abundantly present in human milk. MFG-E8 suppresses the systemic inflammatory responses in adult murine injury models by improving the clearance of dying cells. We hypothesized that exogenous administration of recombinant mouse MFG-E8 could inhibit the exaggerated inflammatory response and lung injury in a murine model of neonatal sepsis. Methods. Neonatal sepsis was induced in 5-to 7-day-old male and female C57BL6 mice using an intraperitoneal injection of cecal slurry. At 1 hour after sepsis induction, a single dose of 40 mg/kg recombinant mouse MFG-E8 or vehicle was administered via retro-orbital injection. All neonates were returned to their mothers as a group. At 10 hours after cecal slurry injection, pups were killed and blood and lung tissues were collected. Control mice underwent a similar procedure with the exception of cecal slurry intraperitoneal injection. Results. Serum lactate dehydrogenase, IL-1b, and IL-6 were significantly increased 10 hours after cecal slurry injection. Treatment with recombinant mouse MFG-E8 decreased these levels by 30%, 56%, and 37%, respectively. Lung morphology was significantly compromised in the vehicle group after cecal slurry injection, whereas the recombinant mouse MFG-E8-treated groups demonstrated a 48% improvement in the lung injury score. Lung IL-6 and MIP-2 protein levels were significantly reduced with recombinant mouse MFG-E8 treatment. Lung neutrophil infiltration as observed by Gr-1 staining and, TUNEL-positive cells were also significantly reduced with recombinant mouse MFG-E8 treatment. Conclusion. Treatment with recombinant mouse MFG-E8 attenuated inflammation and lung injury in murine neonatal sepsis. Thus, MFG-E8 could be developed as a possible therapy for neonatal sepsis. (Surgery 2017;162:349-57.) 
Background. Sepsis remains one of the leading causes of infant death worldwide. It is characterized by uncontrolled inflammatory responses due to proven bacterial infection. Despite improvement in supportive care and the availability of effective antibiotics, no specific therapy targeting the dysregulated inflammatory response is available for neonatal sepsis. Milk fat globule epidermal growth factor-factor 8 (MFG-E8) is a secretory glycoprotein abundantly present in human milk. MFG-E8 suppresses the systemic inflammatory responses in adult murine injury models by improving the clearance of dying cells. We hypothesized that exogenous administration of recombinant mouse MFG-E8 could inhibit the exaggerated inflammatory response and lung injury in a murine model of neonatal sepsis. Methods. Neonatal sepsis was induced in 5-to 7-day-old male and female C57BL6 mice using an intraperitoneal injection of cecal slurry. At 1 hour after sepsis induction, a single dose of 40 mg/kg recombinant mouse MFG-E8 or vehicle was administered via retro-orbital injection. All neonates were returned to their mothers as a group. At 10 hours after cecal slurry injection, pups were killed and blood and lung tissues were collected. Control mice underwent a similar procedure with the exception of cecal slurry intraperitoneal injection. Results. Serum lactate dehydrogenase, IL-1b, and IL-6 were significantly increased 10 hours after cecal slurry injection. Treatment with recombinant mouse MFG-E8 decreased these levels by 30%, 56%, and 37%, respectively. Lung morphology was significantly compromised in the vehicle group after cecal slurry injection, whereas the recombinant mouse MFG-E8-treated groups demonstrated a 48% improvement in the lung injury score. Lung IL-6 and MIP-2 protein levels were significantly reduced with recombinant mouse MFG-E8 treatment. Lung neutrophil infiltration as observed by Gr-1 staining and, TUNEL-positive cells were also significantly reduced with recombinant mouse MFG-E8 treatment. Conclusion. Treatment with recombinant mouse MFG-E8 attenuated inflammation and lung injury in murine neonatal sepsis. Thus, MFG-E8 could be developed as a possible therapy for neonatal sepsis. ( Although the most common pathogens associated with neonatal sepsis are Listeria and Group B Streptococcus, gram-negative (eg, Escherichia coli) sepsis is frequently encountered, especially in cases of necrotizing enterocolitis and spontaneous intestinal perforation. 3, 4 Although septic neonates are treated aggressively with antibiotics, supportive therapies, and surgery when appropriate, no specific agent targeting the dysregulated inflammatory response is currently available. 5, 6 Milk fat globule epidermal growth factor-factor 8 (MFG-E8) is a naturally occurring secretory glycoprotein. It is abundant in human milk and also expressed by numerous mammalian cell types. 7, 8 Hanayama et al 9 identified 2 distinct domains in MFG-E8: an arginine-glycine-aspartate motif, which binds integrins a V b 3 and a V b 5 , and a discoidin domain, which binds phosphatidylserine. These domains determine the function of MFG-E8.
By binding both integrin and phosphatidylserine, MFG-E8 creates a bridge between phagocytes and apoptotic cells, thereby enhancing phagocytosis. 9 Effective clearance of apoptotic cells limits secondary necrosis and, consequently, attenuates inflammation. 10 Furthermore, studies have shown that MFG-E8 suppresses a systemic inflammatory response by reducing excessive production of proinflammatory cytokines (eg, IL-6, IL-1b) through NF-kB activation and translocation to the nucleus. [11] [12] [13] Adult animal models have shown that MFG-E8 mediates engulfment of apoptotic cells, lowers levels of proinflammatory cytokines, and reduces the overall severity of lung injury. 12, 14 The role of MFG-E8 in neonatal sepsis, however, is not known. Here, we hypothesize that recombinant mouse MFG-E8 (rmMFG-E8) would reduce sepsisinduced lung injury and inflammation in murine neonates. In this study, we treated neonatal mice with rmMFG-E8 after the induction of sepsis and subsequently evaluated the effects of this treatment on the severity of organ injury and inflammation, especially in the lungs.
MATERIALS AND METHODS
Experimental animals. Pregnant female C57BL/6 mice were purchased from Charles River Laboratories (Kingston, NY) and were kept in a temperature-and light-controlled room. Standard rodent diet was given to the mice. Pregnant females were closely observed to accurately record the date of birth of their litters. Neonatal mice aged 5 to 7 days were then used for experiments. Pups were kept with their mothers throughout the experiment. adult, house-bred mice (3 males and 3 females) aged 11 to 13 weeks were killed by CO 2 inhalation, and their cecal contents were collected by laparotomy and cecotomy. The cecal contents were pooled and weighed and then suspended with 5% dextrose in normal saline for a concentration of 70 mg/mL. The CS was filtered through a 70-mm filter to remove large particles. With frequent mixing, the CS was aliquoted into 400 mL portions and immediately frozen in liquid nitrogen and stored at À808C. A fresh aliquot was used for each experiment and was used within 2 hours of thawing.
Sepsis induction. Neonatal sepsis was induced in male and female C57BL/6 mice, aged 5 to 7 days, via a CS method adapted from Wynn et al 15 with some modifications. In general, we obtain 6 to 8 pups from one litter; usually they are evenly distributed in sex. However, it was difficult to correctly identify the sex of the newborn mice at an early age of 5 to 7 days. Because they were not distinguished as either male or female, it was difficult to assess the distribution of the sex in this study.
For sepsis induction, neonates were removed as a group from their mothers and were placed on a 378C heating pad. Mice were anesthetized by inhalation with 2.5% isoflurane. Pups were then gently restrained, and CS (0.9 mg/g body weight [BW]) was delivered by intraperitoneal (IP) injection. After recovery from anesthesia, all neonates were again returned to the cage with their mothers as a group. Lung and blood samples were collected 10 hours after CS injection and were stored at À808C until analysis. Control mice in the study underwent a procedure similar to the experimental mice with the exception of the IP injection.
Administration of rmMFG-E8. Septic neonates were randomly assigned to treatment or vehicle groups. The treatment group received a retroorbital injection of 40 mg/kg BW rmMFG-E8 (rmMFG-E8; Cat. No.: 2805-MF-050; R&D Systems, Minneapolis, MN) in a volume of 5 mL/g BW of phosphate-buffered saline 1 hour after IP CS injection. The vehicle group received an equivalent volume of phosphate-buffered saline.
Measurement of lactate dehydrogenase. Blood samples were centrifuged at 7,000 g for 10 minutes, and collected serum was stored at À808C until analysis. Lactate dehydrogenase (LDH) was then measured using a commercial assay kit (Pointe Scientific, Lincoln Park, MI) according to the manufacturer's instructions.
Enzyme-linked immunosorbent assay. Frozen lung tissue samples were crushed into powder, lysed in buffer (10 mM TBS pH 7.5, 1% Triton-X-100, 1 mM ethylenediaminetetraacetic acid, 1 mM aminopolycarboxylic acid) and protease inhibitor cocktail (Thermo Scientific, Rockford, IL), and homogenized with a sonic dismembranator. After measuring the protein concentrations with a DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA), a standardized quantity of protein was loaded onto the enzyme-linked immunosorbent assay (ELISA) plate. Equal volumes of serum samples collected were also loaded onto an ELISA plate. Both serum and lung tissue lysates were analyzed by ELISA kits specific for interleukin 1b (IL-1b) and IL-6 (BD Biosciences, San Jose, CA) and mouse macrophage inflammatory protein-2 (MIP-2) (R&D Systems) according to the manufacturers' instructions.
Histologic evaluation. Lung tissue was placed in 10% formalin prior to embedding in paraffin. Tissue was cut into 5-mm sections and stained with hematoxylin and eosin (H&E) on glass slides. Light microscopy was used to evaluate the degree of lung injury in a blinded fashion. A modified version of the lung injury scoring system from the American Thoracic Society published by Matute-Bello et al 16 was used to generate a lung injury score.
Parameters, such as neutrophils in the alveolar space and in the interstitial space, hyaline membranes, proteinaceous debris filling the airspaces, and alveolar septal thickening, were examined. Based on the presence of each of the parameters, scores per visual field were assessed from 0 to 2 as none, moderate, and severe injury, respectively. The parameter scores were combined using a weighted formulation modified from that described by Matute-Bello et al 16 for a maximum score of 100 per field. The average of the scores per field was calculated as the final lung injury score in each group.
Immunohistochemistry. Immunohistochemistry for granulocyte-differentiation antigen-1 (Gr-1) was performed to assess neutrophil infiltration in the lungs. Paraffin-fixed lung tissues were dewaxed in xylene and rehydrated in a sequence of varying concentrations of ethanol. The slides were heated at 958C for 30 minutes in 0.92% citric acid buffer (Vector Laboratories, Burlingame, CA). Slides were then cooled to room temperature before incubating in 2% H 2 O 2 /60% methanol and blocking in normal goat serum/Tris-buffered saline. Slides were then incubated overnight with anti-Gr-1 antibody (BioLegend, San Diego, CA), counterstained with 49, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA), and observed under a light microscope (Eclipse Ti-S; Nikon, Melville, NY). Gr-1-positive staining cells or neutrophils appearing brown were counted at 2003 magnification in 3 visual fields/section. The mean was computed thereafter.
TUNEL assay. Lung tissue sections were dewaxed and rehydrated as stated above, and were immersed in 20 mg/mL proteinase K at room temperature for 20 minutes. Tissue samples were then stained with a TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) kit (Roche Diagnostics, Indianapolis, IN) and counterstained with DAPI. Apoptotic cells appeared green under a fluorescence microscope and were counted at 2003 magnification in 5 visual fields/ section. The average of the number of apoptotic cells/field was calculated.
Statistical analysis. Data (n = 5-7/group) were compared using 1-way analysis of variance with the Student-Newman-Keuls test or t test where appropriate.
Results are expressed as mean ± standard error of the mean.
RESULTS
Treatment with rmMFG-E8 mitigated organ injury and inflammation in neonatal sepsis. To assess the degree of organ injury induced by sepsis, serum LDH was measured. At 10 hours after CS injection, LDH levels increased by 1.7-fold compared to the control. In contrast, rmMFG-E8 treatment significantly reduced LDH levels by 30% (Fig 1) . Serum IL-1b and IL-6 levels were measured to evaluate the systemic inflammation associated with neonatal sepsis. At 10 hours after CS injection, while IL-1b increased by 4-fold, IL-6 was increased by 98-fold in the vehicle group compared to the control group (Fig 1, B and C) . Treatment with rmMFG-E8 reduced IL-1b by a significant 56%, whereas IL-6 was reduced by 37% (Fig 1, B and C) .
Treatment with rmMFG-E8 attenuated lung injury in neonatal sepsis. To determine lung injury, the lung architecture was examined histologically by using H&E staining at 10 hours after CS injection. As shown in Fig 2, A, lung injury was evident in vehicle neonates with the presence of neutrophils in the alveolar space and interstitial space, the occurrence of hyaline membranes and proteinaceous debris, and increased alveolar septal thickening compared to the control group. However, rmMFG-E8-treated neonates depicted improved lung morphology, compared to the vehicle group (Fig 2, A) . As quantified in Fig 2, B , the histologic lung injury score increased by 4-fold in the vehicle group compared to the control, whereas the score was significantly decreased by 48% in the rmMFG-E8 treatment group.
Treatment with rmMFG-E8 decreased lung inflammation and neutrophil infiltration in neonatal sepsis. We investigated the local inflammatory response induced by neonatal sepsis in the lungs by quantifying lung IL-6 levels. At 10 hours after CS injection, lung IL-6 was 7.5-fold higher in the vehicle group than the control and was significantly reduced by 41% in the rmMFG-E8 treatment group (Fig 3, A) . Moreover, we evaluated neutrophil infiltration in the lungs as an indicator of inflammation by measuring MIP-2 levels (Fig 3,  B) and GR-1 positive cells (Fig 3, C and D) . MIP-2 Effect of rmMFG-E8 on organ injury and inflammation after neonatal sepsis. Male and female C57BL/6 pups were subjected to neonatal sepsis by IP CS injection and treated with phosphate-buffered saline (vehicle) or rmMFG-E8 (40 mg/kg BW) at 1 hour after CS. Serum samples collected at 10 hours after CS were measured for (A) LDH, (B) IL-1b, and (C) IL-6. Serum samples from neonatal mice with neither CS injection nor treatments were included as controls (control) for the experiment. Data shown as mean ± SE and compared by 1-way analysis of variance and Student-Newman-Keuls. *P < .05 versus control; # P < .05 versus vehicle.
Fig 2.
Effect of rmMFG-E8 on lung injury after neonatal sepsis. Lung tissues from control, vehicle, and rmMFG-E8 treatment groups harvested at 10 hours after CS were sectioned, stained with H&E, and examined under light microscopy. levels increased by 5-fold after CS injection in the vehicle group compared to the control (Fig 3, B) . However, MIP-2 levels were significantly reduced by 19% in the rmMFG-E8-treated neonates in comparison with the vehicle group (Fig 3, B) . Gr-1 antibody staining marked a substantial increase of neutrophils by 3-fold in the vehicle compared to the control (Fig 3, D) . In contrast, neutrophil infiltration was significantly reduced by 27% in the rmMFG-E8 treatment group compared to the vehicle (Fig 3, D) . Treatment with rmMFG-E8 reduced TUNELpositive cells in the lungs in neonatal sepsis. To analyze the effects of rmMFG-E8 treatment on the lungs, the TUNEL assay was performed. While no TUNEL-positive cells were detected in the control group, as shown in Fig 4, A, the number of TUNELpositive cells increased by an average of 10 cells/ field in the vehicle group (Fig 4, B) . However, TUNEL-positive cells in the rmMFG-E8-treated group were significantly reduced by 71% compared to the vehicle group (Fig 4, B) .
DISCUSSION
Neonatal sepsis is a highly inflammatory condition culminating in septic shock and multiple organ dysfunction due to uncontrolled activation of the inflammatory system in response to pathogens. Newborns are at increased risk for severe bacterial infection due to their underdeveloped immune system. [17] [18] [19] The initiation of an effective immune response requires innate immune cells, that is, macrophages and dendritic cells. Cytokines produced by these cells are essential for the host defense in response to pathogens.
Cytokines, however, play a vital role in the development of sepsis in neonates. [20] [21] [22] A pathogenic stimulus triggers proinflammatory cytokine secretion from the phagocytes, which in turn promote the release of inflammatory mediators from the neutrophils and T cells. 23, 24 Neutrophils release preformed inflammatory mediators stored in the granules, such as elastase and myeloperoxidase, which results in excessive inflammation leading to tissue damage and organ dysfunction. 25 Therefore, targeting the exaggerated inflammatory response could be beneficial in preventing neonatal sepsis. In the current study using an established murine model of neonatal sepsis, we showed that treatment with rmMFG-E8 after induction of sepsis attenuated organ injury and inflammation and reduced lung neutrophil infiltration and TUNELpositive cells in the lung during neonatal sepsis. Studies have shown that proinflammatory cytokines, such as IL-6 and IL-1b are elevated in the peripheral blood plasma of neonates during early onset of sepsis. [25] [26] [27] [28] In this regard, serum IL-1b and IL-6 were markedly increased 10 hours after CS injection. In contrast, significant reductions of both cytokines were observed after rmMFG-E8 treatment. LDH, an indicator of organ injury, was also elevated after CS injection, which was significantly decreased with rmMFG-E8 treatment. In addition to systemic effects, neonatal sepsis caused severe lung damage, as evidenced by alterations in the histologic appearance of the lung architecture. Treatment with rmMFG-E8 significantly attenuated sepsis-induced lung injury in the newborn mice. Neonatal sepsis-associated increase in lung IL-6 levels was significantly reduced by rmMFG-E8 treatment. Neonatal sepsis also caused neutrophil infiltration in the lungs as observed by MIP-2 levels and Gr-1 positive cells, which was attenuated by rmMFG-E8 treatment. Treatment with rmMFG-E8 also significantly reduced neonatal sepsis-induced TUNEL-positive cells in the lung.
In general, we obtained 50 mL blood from a neonatal mouse at 10 hours after CS injection. The serum obtained thereafter was used for the LDH assay and cytokine analyses. Due to the scarcity of the serum samples, serologic measurements of organ injury other than LDH were not assessed. In addition, because the aim of the study was to determine the effect of rmMFG-E8 on lung injury, other organs, such as the liver and kidneys, were not investigated. In adult injury models of gut and liver ischemia-reperfusion injury, we have previously shown that rmMFG-E8 significantly decreased liver enzymes (aspartate aminotransferase and alanine aminotransferase) and creatinine at 4 hours after reperfusion.
14,29 Therefore, it is possible that the systemic effect observed with rmMFG-E8 treatment in the current study was due to the effect on multiple systems not just the lungs. Additional experiments are warranted, however, to determine whether liver and kidneys are involved in this systemic effect. Nevertheless, these data collectively indicated that treatment with rmMFG-E8 protects neonates against exaggerated inflammatory response and lung injury in neonatal sepsis. This is the first study demonstrating the protective effect of rmMFG-E8 in neonatal sepsis. MFG-E8 is a secretory molecule that is abundant in human milk and is mainly produced by the spleen. 30 It is expressed by numerous mammalian cell types, including macrophages and dendritic cells. 7, 8 The most striking function of MFG-E8 is its ability to act as a tether between phagocytes and apoptotic cells in facilitating clearance of apoptotic cells or phagocytosis.
In the current study, treatment with rmMFG-E8 significantly reduced TUNEL-positive cells in the lungs. It is possible that the decrease in TUNELpositive cells observed in the presence of rmMFG-E8 is due to the clearance of apoptotic cells rather than an actual decrease in apoptosis in the lungs. Efficient clearance of apoptotic cells can inhibit the release of inflammatory and toxic mediators from apoptotic cells and reduce the exaggerated inflammatory response. MFG-E8-mediated apoptotic cell phagocytosis inhibits the mitogen-activated protein kinase and NF-kB pathways. 31 In addition, there is direct evidence that MFG-E8 binds to integrin receptors, a V b 3 or a V b 5 , and inhibits the production of IL-1b in macrophages. In the current study, serum IL-1b levels were significantly reduced in neonatal mice treated with rmMFG-E8. Future studies are warranted to pinpoint the exact mechanism of rmMFG-E8 in neonatal sepsis.
Because the bacterial flora in the neonates qualitatively and quantitatively differ from that of adults, the use of the adult CS is relevant to mimic sepsis in the newborn mice. Neonatal sepsis is often caused by bacterial pathogens transmitted from the mother to infant before or during delivery. The organisms causing neonatal sepsis are colonizers of the maternal genitourinary tract leading to contamination of the amniotic fluid, placenta, cervix, or the vaginal canal. Therefore, the infant acquires the pathogen either in utero or intrapartum. Although Listeria from contaminated foods and vaginal colonization of Group B streptococcus are the most common pathogens they acquire, gram-negative or E coli sepsis is the common cause of mortality in the neonates. 32 Thus, the transfer of bacterial flora from the mother is the common source for infection in the neonates.
There are several limitations that have to be addressed in our study. First, we only assessed organ injury and inflammation parameters at 10 hours after CS injection. This time point was chosen based on our pilot experiment in which, while we observed 100% mortality within 20 hours using 0.9 mg/g CS, no mortality was seen until >10 hours after CS injection. Therefore, as a proof of concept study, we chose a single time point, 10 hours, to determine whether rmMFG-E8 treatment causes any protection in neonatal sepsis.
Second, only a single dose of rmMFG-E8, 40 mg/ kg, was used in the study. This dose was chosen based on our previous experiments in other adult animal organ injury models in which we observed significant decreases in organ injury and inflammatory response in doses as low as 20 mg/kg. 13, 14 We have also previously shown that rmMFG-E8 at a dose of 0.4 mg/20 g mouse showed significantly decreased tumor necrosis factor-a levels in the serum and splenic tissues in an adult endotoxemia model of sepsis. 33 In another study of adult cecal ligation and puncture model of sepsis using recombinant human MFG-E8, we observed significant protection with doses as low as 20 mg/ kg. With higher doses, further reductions in serum injury markers and cytokine levels were seen. 13 The current study showed significant decrease in lung injury score and decreases in circulating and lung cytokine levels indicating significant protection of the lungs with the current dose of rmMFG-E8 treatment. It is possible that higher doses of rmMFG-E8 can exert higher degrees of protection in the lungs in neonatal sepsis. Additional experiments with various doses and time points are warranted to assess optimal dosage and therapeutic window for its beneficial effects.
Third, we have not conducted survival studies of rmMFG-E8 administration in this murine model of neonatal sepsis. We have previously shown that rmMFG-E8 at doses as low as 20 mg/kg improved survival in an adult model of polymicrobial sepsis. 12 In the current study, our pilot study showed 100% mortality within 20 hours using a CS dose of 0.9 mg/g. Therefore, the CS dose needs to be adjusted to achieve an LD50 model prior to engaging in additional experiments. Further studies with varying doses of CS are needed in the future to determine the long-term efficacy of rmMFG-E8 in ameliorating neonatal sepsis.
Another limitation of the study is that the controls in the study did not receive IP injection of the control solution, 5% dextrose. Even though it is highly unlikely that administration of 5% dextrose produces any inflammation or organ injury, it is difficult to rule out what effect the trauma of IP injection has on the neonatal mouse in this study. Another limitation is that we have not measured circulating or tissue levels of MFG-E8 in the control or 10 hours after neonatal sepsis. Previously, however, we have shown that MFG-E8 levels are reduced in the serum and splenic tissues in adult sepsis. 12, 34 Although the measurement of splenic levels of MFG-E8 in the current study would have been valuable, we believe that therapeutically inducible supranormal levels of MFG-E8 would still be beneficial in neonatal sepsis.
We also used a retro-orbital injection route as the delivery method for rmMFG-E8. This route was chosen based on the clinical premise that neonates suffering from sepsis would have a venous line created for continuous delivery of fluids and drugs. Additional studies with minimally invasive routes, such as subcutaneous or intramuscular delivery, could be useful for developing MFG-E8 as a therapeutic strategy for neonatal sepsis. Finally, studies using alternate models, such as delivery of known colony forming units of specific bacterial aliquots, for example, E coli, as opposed to CS injection are warranted for confirming the effect of rmMFG-E8 on neonatal sepsis.
